Phosphofructokinase 1

Phosphofructokinase 1 enables the quantitative detection of fructose-2,6-bisphosphate levels via a coupled-enzyme cell-free assay^[1].
Phosphofructokinase 1 (PFK1) is expressed in a variety of human colorectal cancer (CRC) cell lines, with the highest expression level detected in HT29 cells; in addition, its expression level in radioresistant tumors is significantly higher than that in radiosensitive tumors^[3].
Phosphofructokinase 1 knockdown via siRNA-PFK1 (24 h post-transfection) suppresses glycolytic activity in human colorectal HT29 and HCT116 cells, and lowers glucose consumption, lactate secretion, intracellular ATP content as well as PFK1 enzymatic activity^[3].
Phosphofructokinase 1 knockdown via siRNA (transfection for 24 h; 24-72 h post-transfection) inhibits the proliferation and migration of human colorectal cancer cells HT29 and HCT116, and promotes their apoptosis^[3].
Phosphofructokinase 1 knockdown via siRNA-PFK1 (transfection for 24 h; incubation for 24 h post-irradiation) enhances the radiosensitivity of human colorectal cancer HT29 and HCT116 cells, and reduces cell survival rates after X-ray irradiation at doses of 2 to 8 Gy, with an LD₅₀ value of 6.2 Gy for HT29 cells and 4.2 Gy for HCT116 cells; it also enhances radiation-induced apoptosis of HT29 and HCT116 cells in a dose-dependent manner^[3].
Phosphofructokinase 1 knockdown via siRNA-PFK1 (transfection for 24 h; incubation for 14 days after seeding) reduces the colony-forming ability of HT29 human colorectal cancer cells, and this effect is enhanced after exposure to 2 Gy X-rays^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.